EU grants licence on Cystic Fibrosis drug Orkambi for prescription to children as young as six

The EU has granted a licence to extend the use of the cystic fibrosis drug Orkambi to children as young as six-years-old.

The high price of the drug led to a stand-off between the Government and pharmaceutical company Vertex last year.